This new GM-CSF → CCL17 pathway appears to be active in rheumatoid arthritis patients since circulating CCL17 levels are dramatically reduced upon anti-GM-CSF receptor monoclonal antibody therapy (102). This evidence concerns the gene CCL17 and rheumatoid arthritis.